A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

​ Conditions: B Cell Malignancies; Acute Lymphobkastic Leukemia; Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)

Interventions: Drug: SHB-02-CD19 (anti CD19 CAR-T cells)

Sponsors: Sheba Medical Center

Not yet recruiting Conditions: B Cell Malignancies; Acute Lymphobkastic Leukemia; Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Interventions: Drug: SHB-02-CD19 (anti CD19 CAR-T cells)
Sponsors: Sheba Medical Center
Not yet recruiting